Geron Corp. will enter uncharted territory when it begins the first federally approved human studies on an embryonic stem cell therapy, marking what some consider a major milestone in a field that’s still a long way from commercialization.
The Menlo Park, Calif.-based company plans begin testing a treatment using embryonic stem cells that could fix major spinal cord injuries in people.